NCT02683889View on ClinicalTrials.gov

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
FSGS
Interventions
DRUG

Acthar

patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS

Trial Locations (1)

20005

Medstar Georgetown Transplant Institute, Washington D.C.

All Listed Sponsors
lead

University of Colorado, Denver

OTHER